Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanamem in mild or moderate dementia due to Alzheimer's Disease
NCT06125951Phase 3Active, not recruiting
- Sponsor
- Actinogen Medical Limited
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of emestedastat in Alzheimer's disease (AD) (3 arms), sponsored by Actinogen Medical Limited. Primary endpoints: Integrated cognitive and functional abilities at 36 weeks and Treatment-emergent adverse events at 36 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
emestedastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06125951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125951.